Copper (64Cu) oxodotreotide or Copper Cu 64 dotatate, sold under the brand name Detectnet, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults.

[2] Common side effects include nausea, vomiting and flushing.

[2][3] The U.S. Food and Drug Administration (FDA) approved copper 64Cu dotatate based on data from two trials that evaluated 175 adults.

[4] Trial 1 evaluated adults, some of whom had known or suspected NETs and some of whom were healthy volunteers.

[4] Both groups received copper 64Cu dotatate and underwent PET scan imaging.